PIPELINE
- Pipeline
- Pipeline
PIPELINE
Welcome to our dynamic drug pipeline powered by UniStac® where innovation meets multi-functional medicine.
Our diverse portfolio features a range of multi-target drug candidates, carefully crafted to synergistically coordinate multiple mechanisms of action (MoA). This strategic approach to development empowers us to not only target specific diseases but also expand into related indications, offering a versatile platform with the highest potential for successful outcomes.
| Code | Program / Indication | Target | Development stage | |||||
|---|---|---|---|---|---|---|---|---|
| Discovery | Lead | Preclinical | IND Enabling | Clinical | ||||
| NASH / Fibrosis |
OGB21502 | NASH. Cirrhosis, IPF | GLP-1 x GCG x FGF21 x IL-1 Ra |
|
||||
| OGB21504 | Fibrotic disease |
3 Undisclosed targets |
|
|||||
| Oncology | OGB23501 | Immuno- Oncology |
PD-1 x VEGF x Undisclosed #1 |
|
||||
| OGB23502 | Immuno- Oncology |
PD-1 x VEGF x Undisclosed #1 |
|
|||||
| Code | Program/ Indication |
Target | Development stage |
|
|---|---|---|---|---|
| NASH / Fibrosis |
OGB21502 | NASH. Cirrhosis, IPF | GLP-1 x GCG x FGF21 x IL-1 Ra |
Preclinical |
| OGB21504 | Fibrotic disease |
3 Undisclosed targets |
Discovery | |
| Oncology | OGB23501 | Immuno- Oncology |
PD-1 x VEGF x Undisclosed #1 |
Lead |
| OGB23502 | Immuno- Oncology |
PD-1 x VEGF x Undisclosed #1 |
Discovery |
- ADDRESS
-
#1204, Ace Gwanggyo Tower 2
91 Changnyong-daero, 256 beon-gil
Yongtong-gu, Suwon
Republic of Korea
- TELEPHONE
- +82-31-8014-2861
Copyright © 2022 ONEGENE BT. All Rights Reserved.
